The Spanish Competition Authority initiates proceedings against two pharmaceutical companies for abuse of dominant position (Leadiant Biosciences Spa / Leadiant Biosciences)

The CNMC initiates disciplinary proceedings against Leadiant Biosciences Spa and Leadiant Biosciences LTD for alleged practices prohibited by the Antitrust Law* It is investigating a potential abuse of their dominant market position in Spain involving the manufacture and supply of the drug

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.